1.
Personalizing medicine with clinical pharmacogenetics
by Scott, Stuart A
Genetics in medicine, 2011, Vol.13 (12), p.987-995
2.
Cytochromes P450 and metabolism of xenobiotics
by Anzenbacher, P
Cellular and molecular life sciences : CMLS, 2001, Vol.58 (5-6), p.737-747
3.
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy
by Cronin-Fenton, Deirdre P
Future oncology (London, England), 2014, Vol.10 (1), p.107-122
4.
Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes
by Yeung, John H.K
Phytomedicine (Stuttgart), 2012, Vol.19 (5), p.457-463
5.
Pharmacogenomic–pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer
by Ishiguro, Hiroshi
Breast cancer (Tokyo, Japan), 2019, Vol.26 (5), p.535-543
6.
Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 prob...
by Or, Penelope M.Y
Phytomedicine (Stuttgart), 2012, Vol.19 (6), p.535-544
7.
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive diso...
by Höfer, Peter
European archives of psychiatry and clinical neuroscience, 2012, Vol.263 (5), p.385-391
8.
CYP2D6 in the Metabolism of Opioids for Mild to Moderate Pain
by Leppert, Wojciech
Pharmacology, 2011, Vol.87 (5-6), p.274-285
9.
Heterologous Expression of Human Cytochromes P450 2D6 and CYP3A4 in Escherichia coli and Their Functional Characterization
by Pan, Yan
Protein Journal, 2011, Vol.30 (8), p.581-591
10.
CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants
by Usia, T
Phytomedicine (Stuttgart), 2006, Vol.13 (1), p.67-73
11.
Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib
by Kobayashi, Hiroyuki
Medical oncology (Northwood, London, England), 2016, Vol.33 (6), p.57
12.
The Pharmacokinetics of Paliperidone Versus Risperidone
by de Leon, Jose, M.D
Psychosomatics (Washington, D.C.), 2011, Vol.51 (1), p.80-88
13.
Use of High Doses of Quetiapine in Bipolar Disorder Episodes are not Linked to High Activity of Cytochrome P4503A4 and/or Cytochrome P4502D6
by Khazaal, Yasser
Psychiatric quarterly, 2012, Vol.84 (3), p.329-335
14.
Cytochrome P450 2D6 variants in a caucasian population : Allele frequencies and phenotypic consequences
by SACHSE, C
American journal of human genetics, 1997, Vol.60 (2), p.284-295
15.
Effect of CYP2D610 and APOE Polymorphisms on the Efficacy of Donepezil in Patients With Alzheimer’s Disease
by Zhong, Yuan, MD
The American journal of the medical sciences, 2012, Vol.345 (3), p.222-226
16.
Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4
by Fang, J
Naunyn-Schmiedeberg's archives of pharmacology, 1999, Vol.359 (2), p.147-151
17.
Actual and Potential Drug Interactions Associated with Methadone
by Weschules, Douglas J.
Pain medicine (Malden, Mass.), 2008, Vol.9 (3), p.315-344
18.
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer
by Saladores, Pilar H
Expert review of molecular diagnostics, 2013, Vol.13 (4), p.349-365
19.
Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6()1 and CYP2D6()10 using cell-based models in vitro
by Qu, Qiang
Acta pharmacologica Sinica, 2014, Vol.35 (5), p.685
20.
In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates
by Derks, Michael
Current medical research and opinion, 2009, Vol.25 (4), p.891-902
